Safety and Tolerability of TG1050: A Dose-finding Study

Summary

Methodology: This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection. For all cohorts, patients must be receiving antiviral treatment with either tenofovir disoproxil fumarate (TDF) or entecavir (ENT) for at least two years, and have their HBV infection well-controlled

Timeline

Start

2015-10

Primary completion

2018-11

Completion

2018-11

Drugs

Indications